Iron availability is a critical factor in the growth of Mucorales (5). Here we report the novel use of deferasirox (Exjade; Novartis), an iron chelator recently approved by the U.S. Food and Drug Administration for the treatment of transfusionrelated iron overload (3), as salvage therapy for a patient with progressive rhinocerebral mucormycosis. A 40-year-old man presented to an outside hospita...

Iron resulting from hemoglobin degradation is linked to delayed neuronal injury after intracerebral hemorrhage. Extensive preclinical investigations indicate that the iron chelator, deferoxamine mesylate, is effective in limiting hemoglobin- and iron-mediated neurotoxicity. However, clinical studies evaluating the use of deferoxamine in intracerebral hemorrhage are shortcoming. This article rev...

Acute Ischemic Syndromes To the Editor: Congratulations to Duffy et al1 on their well-written article, “Iron Chelation Improves Endothelial Function in Patients With Coronary Disease.” We completely agree that increased body iron stores may be a risk factor for atherosclerosis and may accelerate endothelial dysfunction in acute ischemic syndromes. Hence, deferoxamine, an iron chelator, should p...

The relationship between the oral efficacy and the acute toxicity of hydroxypyridin4one iron chelators has been investigated to clarify structure-function relationships of these compounds in vivo and to identify compounds with the maximum therapeutic safety margin. By comparing “Fe excretion following oral or intraperitoneal administration of increasing doses of each chelator to iron-overloaded...

Administration in the drinking water of the orally-active iron chelator 1,2-diethyl-3-hydroxypyridin-4-one (CP94) to C57BL/10ScSn mice caused the development of hepatic protoporphyria. This was detected after 1 week and continued as long as the chelator was given (15 weeks). The more hydrophilic 1,2-dimethyl- and 1-hydroxyethyl,2-ethyl-analogues (CP20 and CP102) were also tested, but they were ...

PURPOSE Although toxic to the retina in its native form, the iron chelator deferoxamine (DFO) shows no apparent retinal toxicity when bound to hydroxyethyl-starch (HES). Conjugation of DFO does not alter its iron binding properties. Once bound, iron is no longer active in the production of toxic oxygen intermediates. This investigation seeks to determine whether HES-conjugated DFO (HES-DFO) pro...

abstract background iron overload is a major problem in patients with major thalassemia. an effective and safe iron chelator protocol with high compliance rate plays an important role in treatment of these patients. this study was done to assess the efficacy and safety of the sequential deferoxamine and deferasirox protocol in major thalassemia patients in khuzestan province, iran. material and...

BACKGROUND Iron is essential for cell proliferation and viability. It has been reported that iron depletion by a chelator inhibits proliferation of some cancer cells. Deferasirox is a new oral iron chelator, and a few reports have described its effects on lymphoma cells. The goal of this study was to determine the anticancer effects of deferasirox in malignant lymphoma cell lines. METHODS Thr...